In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
AI superintelligence startup promises new drug discoveries
This article by Greg Licholai discusses how AI is revolutionising drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the charge by using AI to accelerate scientific breakthroughs. Lila focuses on creating "scientific superintelligence" through autonomous labs, while Recursion maps human biology to discover new treatments faster.
-
Marking the Path Ahead: Integrating Oncology Biomarkers Into Clinical Development' has published
In this article, ICON experts discuss strategies to implement biomarkers in clinical development, saving sponsors time and money while positioning therapies for success.
-
ICON and Mural Health Technologies partner to improve trial subject experience
This article discusses Mural Health’s partnership with ICON to improve clinical trial subject and site experiences using the Mural Link platform. Mural Health’s payment alternatives, including the fee-free debit card, will help ICON avoid financial barriers that hinder participation in clinical trials.
-
Mural Health, ICON Partner to enhance site experience in clinical trials
This article discusses how ICON will use Mural Link’s functionality related to clinical trial participant support services, communication tools, and reporting and analytics capabilities.
-
ICON partners with global healthcare leaders to procure renewable power in China
Aligned with ICON's sustainability strategy, this collaboration of 12 companies will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines.
-
The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Partnering for success in early phase clinical development
Early-phase clinical trials serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market. However, these early stages present significant challenges—nearly half of all drugs entering clinical trials do not make it past phase 1. With the average phase 1 trial costing millions of dollars and consuming valuable time, biotechs have little room for error. This article discusses how partnering with a CRO can benefit a small biotech - helping to fill the gaps in knowledge, resources infrastructure.
-
Combination therapies may be the future of oncology – How can we navigate development challenges today?
In this article, ICON experts discuss common ways oncology therapies are combined to achieve synergistic effects, and considerations oncology developers should employ to de-risk combination therapy development.
-
ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
Standing out in a crowded precision oncology landscape
A 2024 ICON survey of over 100 oncology developers’ pipelines reflected a diverse and highly complex landscape of emerging precision oncology therapies. These emerging therapies in oncology are displacing traditional toxic treatments such as chemotherapy and radiation.
